Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 1/20 | 0.42 |
| ▸ | LIPC | P11150 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1855162 | 0.90 | NAAA (0.60) | NAAASMN1; SMN2SIGMAR1TMEM97HDAC3 | |
| SCHEMBL1854798 | 0.89 | NAAA (0.54) | NAAASMN1; SMN2SIGMAR1TMEM97HDAC3 | |
| SCHEMBL1857222 | 0.87 | NAAA (0.55) | NAAASMN1; SMN2SIGMAR1TMEM97HDAC3 | |
| SCHEMBL1855455 | 0.85 | NAAA (0.53) | NAAASMN1; SMN2SIGMAR1TMEM97HDAC3 | |
| SCHEMBL1858834 | 0.84 | NAAA (0.52) | NAAASMN1; SMN2SIGMAR1TMEM97HDAC3 | |
| SCHEMBL1850770 | 0.84 | NAAA (0.52) | NAAASMN1; SMN2SIGMAR1TMEM97HDAC3 | |
| SCHEMBL1853372 | 0.83 | ALDH1A1 (0.56) | NAAASMN1; SMN2SIGMAR1TMEM97HDAC3 | |
| SCHEMBL1856397 | 0.83 | NAAA (0.55) | NAAASMN1; SMN2SIGMAR1TMEM97ALDH1A1 | |
| SCHEMBL1854062 | 0.83 | NAAA (0.51) | NAAASMN1; SMN2SIGMAR1TMEM97 | |
| SCHEMBL1858157 | 0.83 | TMEM97 (0.53) | NAAASMN1; SMN2SIGMAR1TMEM97HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470102-B1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | MERCK SERONO SA (CH) | 2011-05-25 | — | — | EP | claimed |
| EP-1732534-B1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | SERONO LAB (CH) | 2008-07-23 | — | — | EP | claimed |
| US-20070185118-A1 | Use of methylene amide derivatives in cardiovascular disorders | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-08-09 | — | — | US | claimed |
| EP-1470102-B1 | SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | MERCK SERONO SA (CH) | 2011-05-25 | — | — | EP | disclosed |
| US-7592477-B2 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) | LABORATOIRES SERONO SA (CH) | 2009-09-22 | — | — | US | disclosed |
| EP-1732534-B1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | SERONO LAB (CH) | 2008-07-23 | — | — | EP | disclosed |
| EP-1732534-A1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | Applied Research Systems ARS Holding N.V. (AN) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005082347-A1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | APLLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-09-09 | — | — | WO | disclosed |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | APPLIED RESEARCH SYSTEMS ARS (NL) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185118-A1 | Use of methylene amide derivatives in cardiovascular disorders | TNNI3, TNNT2, ADM2 | NAAA 684/4885SMN1; SMN2 2542/4885SIGMAR1 2165/4885 |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | PTPRS, PTPA, PTPMT1 | NAAA 1643/4885SMN1; SMN2 4878/4885SIGMAR1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.